These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26136386)

  • 21. CHA
    Faganello G; Barbati G; Russo G; Scagnetto A; Mazzone C; Mottolese BD'; Zaccari M; Sinagra G; Lenarda AD; Cioffi G
    Pediatr Cardiol; 2020 Jun; 41(5):1051-1057. PubMed ID: 32372107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study.
    Olesen JB; Lip GY; Lane DA; Køber L; Hansen ML; Karasoy D; Hansen CM; Gislason GH; Torp-Pedersen C
    Am J Med; 2012 Aug; 125(8):826.e13-23. PubMed ID: 22579139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis.
    Senoo K; Lane DA; Lip GY
    Int J Cardiol; 2015 Feb; 181():247-54. PubMed ID: 25528530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
    Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
    Lip GY; Piotrponikowski P; Andreotti F; Anker SD; Filippatos G; Homma S; Morais J; Pullicino P; Rasmussen LH; Marín F; Lane DA;
    Thromb Haemost; 2012 Dec; 108(6):1009-22. PubMed ID: 23093044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy.
    Hansen ML; Jepsen RM; Olesen JB; Ruwald MH; Karasoy D; Gislason GH; Hansen J; Køber L; Husted S; Torp-Pedersen C
    Europace; 2015 Jan; 17(1):18-23. PubMed ID: 25231909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of CHA2DS2-VASc Score for Prediction and Ruling Out of Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention.
    Açikgöz SK; Açikgöz E; Çiçek G
    Angiology; 2020 May; 71(5):411-416. PubMed ID: 32030991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
    Jover E; Roldán V; Gallego P; Hernández-Romero D; Valdés M; Vicente V; Lip GY; Marín F
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):627-33. PubMed ID: 22609214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Puurunen MK; Kiviniemi T; Schlitt A; Rubboli A; Dietrich B; Karjalainen P; Nyman K; Niemelä M; Lip GY; Airaksinen KE
    Thromb Res; 2014 Apr; 133(4):560-6. PubMed ID: 24461143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy.
    Paoletti Perini A; Bartolini S; Pieragnoli P; Ricciardi G; Perrotta L; Valleggi A; Vergaro G; Michelotti F; Boggian G; Sassone B; Mascioli G; Emdin M; Padeletti L
    Europace; 2014 Jan; 16(1):71-80. PubMed ID: 23828875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion.
    Falsetti L; Viticchi G; Tarquinio N; Silvestrini M; Capeci W; Balloni A; Catozzo V; Gentile A; Pellegrini F
    J Cardiovasc Med (Hagerstown); 2014 Aug; 15(8):636-41. PubMed ID: 24978663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased risk of first-ever stroke in younger patients with atrial fibrillation not recommended for antithrombotic therapy by current guidelines: a population-based study in an East Asian cohort of 22 million people.
    Chang KC; Wang YC; Ko PY; Wu HP; Chen YW; Muo CH; Sung FC; Li TC; Hsu CY
    Mayo Clin Proc; 2014 Nov; 89(11):1487-97. PubMed ID: 25444485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: role of incorporating PR prolongation.
    Chan YH; Yiu KH; Lau KK; Yiu YF; Li SW; Lam TH; Lau CP; Siu CW; Tse HF
    Atherosclerosis; 2014 Dec; 237(2):504-13. PubMed ID: 25463082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project.
    Philippart R; Brunet-Bernard A; Clementy N; Bourguignon T; Mirza A; Babuty D; Angoulvant D; Lip GY; Fauchier L
    Eur Heart J; 2015 Jul; 36(28):1822-30. PubMed ID: 25994754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atrial fibrillation patients categorized as "not for anticoagulation" according to the 2014 Canadian Cardiovascular Society algorithm are not "low risk".
    Lip GY; Nielsen PB; Skjøth F; Rasmussen LH; Larsen TB
    Can J Cardiol; 2015 Jan; 31(1):24-8. PubMed ID: 25547546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CHA
    Ye S; Qian M; Zhao B; Buchsbaum R; Sacco RL; Levin B; Di Tullio MR; Mann DL; Pullicino PM; Freudenberger RS; Teerlink JR; Mohr JP; Graham S; Labovitz AJ; Estol CJ; Lok DJ; Ponikowski P; Anker SD; Lip GY; Thompson JL; Homma S;
    Eur J Heart Fail; 2016 Oct; 18(10):1261-1266. PubMed ID: 27444219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between CHADS2 and CHA2 DS2 -VASc score in a stroke cohort with atrial fibrillation.
    Giralt-Steinhauer E; Cuadrado-Godia E; Ois A; Jiménez-Conde J; Rodríguez-Campello Á; Soriano C; Roquer J
    Eur J Neurol; 2013 Apr; 20(4):623-8. PubMed ID: 22834861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry].
    De Caterina R; Renda G; Sangiuolo R; Attena E; Di Lecce L; Romeo F;
    G Ital Cardiol (Rome); 2014 Feb; 15(2):99-109. PubMed ID: 24625849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan.
    Chao TF; Wang KL; Liu CJ; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Liao JN; Chen TJ; Chiang CE; Lip GY; Chen SA
    J Am Coll Cardiol; 2015 Sep; 66(12):1339-47. PubMed ID: 26383720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.